Skip to content

To compare safety and efficacy of topical Tacrolimus (0.03%) and dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis.

To compare safety and efficacy of topical Tacrolimus (0.03%) and dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis. - Tacro vs Dexa for subepithelial infiltrates.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033956
Enrollment
38
Registered
2018-08-31
Start date
2017-01-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal subepithelial infiltrates

Interventions

The TACRO group received tacrolimus 0.03% ointment twice daily for 6 months DEXA group received dexamethasone 0.05% ointment twice daily for 6 months.

Sponsors

Laser Eye Clinic Noida
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Eligibility criteria were an age of 18 years or older, the presence of ocular symptoms like diminution of vision (corrected distance visual acuity of 6/9 Snellen or worse) for at least 4 weeks with SEIs following AK

Exclusion criteria

Exclusion criteria: Patients who received any topical or systemic medications, had ocular disease like uveitis, glaucoma, or active keratitis, used corticosteroid eye drops; and those who had any ocular operations were excluded from the study.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure was mean change in baseline in the subepithelialinfiltrate (SEI) score measured at four time pointa (baseline, 1 month, 3 months & six months)

Secondary

MeasureTime frame
Changes in visual acuity and intraocular pressure (safety outcomes), and the incidence of adverse events were secondary outcome measures.

Countries

Asia(except Japan)

Contacts

Public ContactDeshbandhu Sood

Citizen Right Protection Forum NGO

brahul_2371@yahoo.co.in919817062276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026